Background. Clostridium difficile is a leading cause of nosocomial infection. The role of cytokine interleukin-27 (IL-27) in the immunopathology of C. difficile infection (CDI) remains unknown.
Clostridium difficile is a gram-positive, spore-forming, anaerobic bacterium that causes antibiotic-associated diarrhea, pseudomembranous colitis, toxic megacolon, and death [1, 2] . In the United States, over 500 000 cases of C. difficile infection (CDI) occur annually, resulting in 15 000 to 20 000 deaths [3] . The continued increase in CDI suggests that it has surpassed other pathogens in causing hospital-acquired infections. Standard treatment for CDI is antibiotic therapy, commonly vancomycin, fidaxomicin, or metronidazole. However, 20% of individuals will develop recurrent episodes of CDI [4] . The Centers for Disease Control and Prevention recently identified CDI as an "urgent threat" in its recent report on antibiotic resistance threats in the United States [5] , highlighting an urgent need for new therapies.
The interaction between C. difficile and host immune system is critical for the pathogenesis of CDI and clearance of the pathogen. Recent studies have suggested an important role of host factors in the immunopathology of CDI. In fact, host factors, such as interleukin (IL)-1β [6] , IL-22 [7] , IL-25 [8] , leptin [9] , nucleotide-binding oligomerization domain 1 (Nod1) [10] , and MyD88 [11] , have been observed to be essential for host survival following C. difficile infection; in addition, IL-23 played a pathogenic role during CDI in mice [12] . Moreover, clinical studies demonstrated that the magnitude of the inflammatory response, as measured by fecal cytokine IL-8 and CXCL-5, correlated more closely with severity and duration of infection than with the C. difficile burden [13] . Thus, host mediators may play a fundamental role in the immune response during CDI.
IL-27 is a heterodimeric regulatory cytokine of the IL-12 family, which is mainly produced by antigen-presenting cells (APCs), including dendritic cells, macrophages, and B cells upon activation [14] . IL-27 signals through a receptor complex composed of T-cell cytokine receptor (TCCR)/WSX-1 and gp130; the former confers ligand specificity and the latter is shared by other IL-6 family cytokines [15] . IL-27 has been shown to play a pathogenic role in T cell-dependent intestinal colitis [16] . However, a more recent study demonstrated that oral delivery of IL-27 recombinant bacteria attenuated immune colitis in mice [17] . Therefore, the role of IL-27 in intestinal immunity and inflammation has not been fully elucidated. In this study, we used the murine model of C. difficile colitis to test the role of IL-27 signaling during intestinal infection. Mice lacking IL-27 signaling had decreased clearance of C. difficile from the gut lumen and increased disease severity. Administration of recombinant IL-27 enhanced C. difficile clearance and reduced CDI-associated mortality. Therefore, IL-27 plays a critical role in host defense against C. difficile infection.
MATERIALS AND METHODS

Study Population
This study was conducted in The First Affiliated Hospital of Chongqing Medical University, and approved by the Institutional Review Board of The First Affiliated Hospital of Chongqing Medical University. In this study, we approached all hospitalized patients who had diarrhea (either on admission or during their hospitalization) between 25 June 2015 and 16 Jan 2017, and obtained written informed consent. Positivity of CDI was based on the presence of C. difficile toxins in stool samples of patients through a toxin A/B (TcdA/TcdB) enzymelinked immunosorbent assay (ELISA), which was also confirmed by a positive C. difficile culture in stool samples of patients in the clinical microbiology laboratory. CDI-negative samples were derived from patients suspected of various other intestinal diseases but confirmed negative for tissue pathology upon colonoscopy examination. These CDI-negative patients were actually diagnosed as transient diarrhea related to laxatives or tube feeds. In addition, we recruited healthy individuals as controls. For all participants, we collected information on demographic characteristics, clinical presentation, medications, laboratory findings, and health care exposures. We retrieved the initial blood and stool specimens submitted to the microbiology laboratory for testing within 48 hours of submission. Blood and stool specimens were aliquoted and stored at −80°C upon receipt.
Bacterial Culture
C. difficile strains 630, VPI 10463 (ATCC 43255) and VPI 11186 were cultured and maintained at 37°C in beef heart infusion supplement (BHIS) media (BD Biosciences, Franklin Lakes, NJ) in an anaerobic environment (BBL GasPak Plus system; BD Biosciences). They were then subcultured under the same conditions for 5 hours before infection.
Mice
C57BL/6 mice aged 6-8 weeks were obtained from and raised at Chongqing Medical University. IL-27R-deficient (WSX-1 −/− ) mice raised on C57BL/6 background were purchased from the Jackson Laboratory. All animal experiments were done in accordance with the Institutional Animal Care and Use Committee's guidelines at the Chongqing Medical University.
Preparation of Culture Supernatants and Heat-Inactivated Bacterial Cell
Extracts
C. difficile strains were cultured at 37°C for 48 hours as described above. The culture supernatants were prepared by filtration though a sterilizing filter (pore size 0.2 μm; Corning, Corning, NY). The bacterial pellets were washed with water once, resuspended in the original volume of water, and heat inactivated at 95°C for 30 minutes.
Murine Model for C. difficile Infection
A characteristic murine C. difficile infection model has been established as described previously [18] . Briefly, C57BL/6 mice received gentamicin (50 mg/mL), metronidazole (5 mg/mL), colistin (25 mg/mL), and vancomycin (50 mg/mL) in their drinking water for 3 days followed by 2 days of fresh water and a subsequent single intraperitoneal injection of clindamycin (10 mg/kg) 1 day prior to infection with a vegetative C. difficile (strain VPI 10463).
Immunostimulation Assay
Monocyte-derived dendritic cells (DCs) were generated as previously described [19] . Dendritic cells were then incubated with lipopolysaccharide (1 μg/mL), C. difficile (multiplicity of infection [MOI] 1:10), or culture supernatants, at the indicated times poststimulation, the levels of cytokines were determined.
Quantitative Real-Time PCR
Total cellular RNA was extracted from dendritic cells (QIAGEN). Quantitative real-time polymerase chain reaction (PCR) analysis for IL-27 EBI3, p28, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was performed using specific primers Quantitect Primer/Probe assays (QIAGEN). An average value of gene expression after GAPDH normalization was used as a calibrator to determine the relative levels of target gene. The relative expression of target genes was calculated using the 2 △C(t) method.
C. difficile Quantification
Cecal contents were suspended in deoxygenated phosphate buffered saline (PBS), and 10-fold dilutions of the suspension were plated anaerobically on beef BHIS plates containing taurocholate, d-cycloserine, and cefoxitin for specific selection of C. difficile. Plates were placed in a 37°C incubator within the anaerobic chamber overnight.
Mouse Pathology
At the indicated time after C. difficile infection, mice were sacrificed and ceca were harvested. Tissue was fixed for 24 hours in Bouin's solution, washed, and then stored in 70% ethanol prior to processing for hematoxylin-eosin (H&E) staining. The histologic severity of enteritis was graded using a scoring system reported previously [18] . Briefly, the grading takes into account the following features: (1) neutrophil margination and tissue infiltration, (2) hemorrhagic congestion and edema of the mucosa, and (3) epithelial cell damage. A score of 0 to 3 was assigned to each of these parameters. The overall score was the sum of each component score. All sections were examined by a single blinded histopathologist.
Measurement of Cytokine/Chemokine
The concentrations of murine interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), IL-6, keratinocyte-derived chemokine (KC/CXCL1), and IL-10 were determined with commercially available ELISA kits from Neobioscience, while IL-17A, IL-23, and IL-27 levels were determined by ELISA kits from R&D Systems, according to the manufacturer's instructions.
Flow Cytometric Analysis
Single-cell leukocyte suspensions of lamina propria cells were generated from mouse colons as described previously [10] . Cell counts were characterized accordingly with PerCP-conjugated anti-CD45, APC-conjugated anti-CD11b, FITC-conjugated anti-Ly6G, PE-cy5-conjugated anti-F4/80, and PE-conjugated anti-CD3 monoclonal antibodies (BD Pharmingen). The absolute numbers of CD11b + Ly6G + neutrophils, CD11b + F4/80 + macrophages, and CD3 + T lymphocytes were then quantified by dividing the number of positive cellular events by the number of bead events and multiplying the result by the bead concentration using a FACScan flow cytometer (Becton Dickinson).
Antibody-Mediated Neutralizations In Vivo
IL-27 neutralization was performed by intraperitoneal administration of 50 µg of anti-IL-27 antibodies (R&D systems) on day 0 (same day as C. difficile infection), followed by booster doses of 50 µg on day 1. Sample harvesting and processing were then performed at indicated times.
IL-27 In Vivo Treatment
C57BL/6 mice were treated with a dose of 0.5 µg recombinant IL-27 protein 2 hours after infection with C. difficile. In parallel, mice were injected solely with saline as control.
Statistical Analysis
Data are expressed as box-and-whisker diagrams unless indicated otherwise. Differences between patients and volunteers, or WT and WSX-1 −/− mice, were analyzed by Mann-Whitney U test. Survival was compared by Kaplan-Meier analysis followed by a log rank test. Values of P < .05 were considered statistically significant.
RESULTS
IL-27 Concentrations Increased During Human CDI
To obtain insight into IL-27 production during CDI, we measured IL-27 protein levels in sera and stools from 72 CDI-negative and 76 CDI-positive patients (Supplementary Table 1 ). Significant increases in serum IL-27 protein concentrations were observed in CDI patients when compared to patient and healthy controls ( Figure 1A ). There was no apparent correlation between serum IL-27 and the severity of disease: serum IL-27 did not correlate with red blood cells (r = 0.03, P = .45), albumin levels (r = −0.11, P = .56), leukocytes (r = 0.28, P = .076), creatinine levels (r = 0.14, P = .23), or blood urea nitrogen (r = −0.15, P = .48). Furthermore, IL-27 protein concentrations were also significantly elevated in the stools from patients with CDI when compared with patient and healthy controls ( Figure 1B) . Therefore, human CDI is associated with a systemic and local increase of IL-27 production.
CDI Induced Upregulated Expression of IL-27 in Human DCs
Because antigen-presenting cells, such as DCs, are the major source of IL-27 upon infection [20] , we stimulated human DCs with live C. difficile VPI 10463 to determine the expression of IL-27. As shown in Figure 2A , quantitative real-time PCR analysis showed that expression levels of IL-27p28 and EBI3 subunits were markedly elevated in DCs upon C. difficile stimulation. In accordance, the protein concentrations of IL-27 released from DCs upon C. difficile VPI 10463 stimulation were significantly enhanced ( Figure 2B ). Treatment with conditioned supernatants from C. difficile VPI 10463 was also associated with a significant increase of IL-27 in DCs, while prior heat treatment of live C. difficile VPI 10463 resulted in a significant decrease in DCs Differences between groups were assessed by one-way ANOVA analysis (n = 5). **P < .01, ***P < .001 when compared to unstimulated cells at the same time. C, DCs were infected with C. difficile at multiplicity of infection of 1:10 (living or heat-killed C. difficile) or medium supernatants from overnight cultures of the C. difficile VPI 10463 or left untreated. IL-27 levels were determined by ELISA 24 hours after stimulation. Differences between groups were assessed by one-way ANOVA analysis (n = 5). ***P < .001 when compared with PBS-treated cells, # P < .05 when compared with live VPI 10463. Abbreviations: CD, C. difficile; LPS, lipopolysaccharide; PBS, phosphate buffered saline.
( Figure 2C ). Furthermore, both toxigenic (630) and nontoxin-producing (VPI 11186) strains of C. difficile induced IL-27 secretion, suggesting that the secretion of IL-27 was independent of TcdA and TcdB ( Figure 2C ). Collectively, these findings indicate that C. difficile infection induced DCs to produce IL-27.
IL-27 Was Upregulated in Murine CDI
To study the role of IL-27 during CDI at the tissue level, we infected WT mice with C. difficile VPI 10463 by gastric gavage. Mice received antibiotics for 5 days prior to infection and were infected with C. difficile. Infection with C. difficile was associated with a significant increase in sera and cecal IL-27 protein production 3 days after inoculation ( Figure 3A and B) .
IL-27 Signaling Was Required for Host Survival During Murine CDI
Having observed increased IL-27 expression during human and murine CDI, we hypothesized that IL-27 may play an important role in the immunopathology of CDI. We infected antibiotic-treated WT and IL-27 receptor knockout (WSX-1 −/− ) mice with C. difficile VPI 10463, and WSX-1 −/− mice showed more significant weight loss than WT mice ( Figure 4A) . Notably, the survival rate of infected WSX-1 −/− mice was significantly lower U test) . B, Survival was monitored until 2 weeks postinfection. Comparison between groups was done by Kaplan-Meier analysis followed by log-rank tests.*P < .05 when compared with WT mice after CDI. C, Representative H&E staining of cecal tissues and tissue pathology scores of cecal tissues from WT and WSX-1 −/− mice on day 3 of CDI. The histologic severity of enteritis was graded taking into account the following features: epithelial cell damage, neutrophil margination, hemorrhagic congestion, and edema of the mucosa. Data were expressed as mean ± SD. *P < .05 when compared between groups denoted by horizontal lines (t test). D, C. difficile bacterial burden in cecal contents from WT and WSX-1 −/− mice on day 3 of CDI. *P < .05, ***P < .001 when compared between groups denoted by horizontal lines (Mann-Whitney U test). Abbreviation: PBS, phosphate buffered saline.
than that of WT mice ( Figure 4B ). In addition, WSX-1 −/− mice had significantly shorter colon length, a measure of more severe colitis, when compared to WT mice (Supplementary Figure 1) . To understand the cause of increased mortality in WSX-1 −/− mice associated with C. difficile infection, we analyzed tissue histology according to the following features: epithelial cell damage, neutrophil margination, hemorrhagic congestion, and edema of the mucosa. Clinical scores for WSX-1 −/− mice were more severe than those of WT mice ( Figure 4C ). Furthermore, significantly higher numbers of C. difficile were found in the intestinal contents from cecum and colon of infected WSX-1 −/− mice when compared with WT mice (Figure 4D ), indicating that the cause of increased mortality in WSX-1 −/− mice was associated with decreased clearance of C. difficile in the intestine.
To further investigate the protective role for IL-27 signaling seen in gene knockout mice, we used a second murine model, in which IL-27 was neutralized using a neutralization antibody. IL-27-neutralized mice had a significantly increased mortality when compared with isotype control mice (Supplementary Figure 2A) . Concurrently, IL-27-neutralized mice had a significantly increased clinical score as compared to isotype controls (Supplementary Figure 2B) .
IL-27 Signaling Impacted Intestinal Inflammation During Murine CDI
To understand how IL-27 shaped intestinal immunity during CDI, we then evaluated protein levels of inflammatory cytokines in cecal tissue after C. difficile VPI 10463 challenge. As shown in Figure 5 , the amounts of murine IL-6, KC, IL-17A, and IL-23 in cecal lysates were significantly higher in WSX-1 −/− mice when compared with WT mice at 2 or 3 days after infection. However, IFN-γ and IL-10 levels were significantly decreased in WSX-1 −/− mice when compared with WT mice at 1, 2, or 3 days after infection.
Administration of Recombinant IL-27 Provided Protection to Mice Against
CDI-Associated Mortality and Morbidity
To further determine whether IL-27 was sufficient to reduce mortality and morbidity during CDI and whether it could serve as an immunoadjuvant, we examined the effects of IL-27 administration on CDI. IL-27 administration 2 hours after C. difficile VPI 10463 challenge significantly decreased weight loss compared with vehicle-treated control animals ( Figure 6A ). IL-27 treatment was capable of reducing CDI-associated mortality ( Figure 6B ). In addition, IL-27-treated mice had significantly longer colon length compared with vehicle-treated control animals (Supplementary Figure 3) . Immunohistological evaluation of the cecum showed that IL-27 significantly decreased CDI-associated tissue pathology ( Figure 6C ). Importantly, IL-27 treatment in C. difficile-infected mice significantly lowered the density of C. difficile in the cecum ( Figure 6D ). Furthermore, IL-27 treatment significantly decreased protein levels of IL-6, KC, IL-17A, and IL-23, but enhanced the production of IL-10 and IFN-γ in the cecal tissue after C. difficile challenge (Figure 7 ).
DISCUSSION
The contribution of the host immune factors to the resolution of CDI remains incompletely understood. In this study, we demonstrated a protective role for IL-27 in the immunopathology of C. difficile infection. IL-27 protein levels were elevated in humans 1000 500 IL-6 (pg/mL) Interleukin-27 (IL-27) deficiency regulated cytokine and chemokine production during Clostridium difficile infection. Cytokine and chemokine production in cecal tissues from wild-type (WT) and WSX-1 −/− mice on day 1, 2, or 3 of C. difficile VPI 10463 infection was determined by enzyme-linked immunosorbent assay. *P < .05, **P < .01, ***P < .001 when compared with WT mice at the same time point (Mann-Whitney U test). Abbreviations: IFN-γ, interferon-gamma; KC, keratinocyte-derived chemokine; TNF-α, tumor necrosis factor-alpha.
and mice with CDI compared with negative controls. IL-27 receptor-deficient (WSX-1 −/− ) mice were defective in the clearance of C. difficile, and they displayed increased disease severity and higher mortality compared with WT mice after C. difficile infection. More importantly, the ability of IL-27 administration after the onset of CDI to significantly reduce mortality and morbidity and to enhance the clearance of C. difficile in mice suggests that IL-27 may have therapeutic effects on CDI. IL-27 is a cytokine with strikingly diverse influences on the host immune response [14, 15] . Various studies have shown a multifaceted role of IL-27 in the immune response during various infectious diseases. IL-27 has been shown to be able to promote the development of postinfluenza Streptococcus pneumoniae or Staphylococcus aureus pneumonia [21, 22] , and IL-27 had the ability to impair antibacterial host defense in the lung during sepsis [23] . Timed action of IL-27 could protect against immunopathology while preserving defense in influenza during lung infection [24] . In addition, IL-27 limited type 2 immunopathology following parainfluenza virus infection [25] . These studies indicated that IL-27 plays a pathogenic role in bacterial infections but a protective role in influenza virus infections in the lung. Our present study further demonstrated that IL-27 was essential for intestinal homeostasis and defense against C. difficile infection. Therefore, IL-27 plays a different immunoregulatory role in the pathogenesis of different infectious diseases. Likewise, IL-23-deficient mice were more susceptible to bacterial infections in the lung corresponding with greater bacterial dissemination [26, 27] , but a lack of IL-23 was protective against mortality and morbidity associated with C. difficile infection [12] . Furthermore, IL-25 could limit IL-17 expression [28] , and IL-17 was found to be essential for protection against Streptococcus pneumoniae or Staphylococcus aureus infections [29, 30] . However, IL-25 could reduce mortality and morbidity and enhance integrity of gut epithelial barrier during CDI [8] , and IL-17 knockout mice were more resistant to CDI than WT mice [31] . What underlying mechanisms mediate the ability of IL-27 to attenuate pathologic effects in CDI? We found that IL-27 could modulate the inflammatory responses in the colon during C. difficile infection. Our experiments showed that the amounts of IL-17A and IL-23 in cecal lysates were significantly higher, while IFN-γ and IL-10 were significantly lower, in WSX-1 −/− mice during CDI when compared with WT mice. Furthermore, IL-27 treatment significantly decreased protein levels of IL-17A and IL-23, but enhanced the production of IL-10 and IFN-γ in the cecal tissues from WT mice after C. difficile challenge. Previous studies have demonstrated that IL-27 could repress IL-23 production in dendritic cells [32] , and it could limit IL-17 expression in T cells [14, 15] . On the other hand, IL-27 promoted the production of IFN-γ by naive T cells [33] , and IFN-γ production was reduced in the absence of IL-27 signaling during T-cell-dependent colitis [16] . In addition, IL-27 has been reported to stimulate the production of IL-10 [34] , and Lactococcus lacti encoding IL-27 reduced colitis in mice by increasing the production of IL-10 [17] . Because both IL-17 and IL-23 have been shown to play a deleterious role during CDI [12, 31] , while both IFN-γ and IL-10 mediated protection against CDI [35, 36] , it is plausible that IL-27 contributed to host defense against C. difficile infection partly through downregulated production of IL-23 and IL-17, but upregulated production of IFN-γ and IL-10. However, we could not exclude the possibility that additional immune mediators regulated by IL-27 may play a role. In addition, in vitro studies have characterized IL-27 as a mediator of intestinal epithelial barrier protection via transcriptional activation of anti-inflammatory and antibacterial target genes [37] , further supporting a protective role of IL-27 in intestinal immunity during bacterial infections.
There are a few important limitations to this study. First, we have demonstrated that IL-27 protein levels were elevated in the blood and stools from patients with CDI, suggesting the relevance of IL-27 in human C. difficile-associated colitis and disease. However, we were unable to determine correlation between IL-27 levels and disease severity, and we acknowledge this could only be definitively established in a large cohort of human patients with CDI. Second, while dendritic cells are considered as the major source of IL-27 and we found that CDI could induce dendritic cells to produce IL-27, there are multiple potential sources of IL-27, including epithelial cells and T cells [15, 38] . Therefore, the source of IL-27 and the factors regulating IL-27 secretion during CDI require further studies. Finally, further examination is required to understand how IL-27 influences the expression of IL-17, IL-23, IFN-γ, and IL-10 in intestinal immunity to mediate protection during CDI.
In conclusion, this study suggests a previously unrecognized role for IL-27 signaling in limiting immunopathology and preventing death during CDI, which may provide new insight for IL-27-mediated protection against C. difficile-associated colitis and disease.
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